News | February 18, 2023
Lupin receives EIR from USFDA for injectable facility in Nagpur
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Subscribe To Our Newsletter & Stay Updated
